Mutation at the HPRT locus in patients with neurocysticercosis treated with praziquantel.
Praziquantel (PZQ) is the drug of choice in the treatment of neurocysticercosis (NC), a parasitic disease caused by Taenia solium larvae. Variant frequencies at the hprt locus were analyzed in a group of NC patients before and after treatment with PZQ as well as in two control groups: healthy donors and non-parasitic neurological patients. Data show that PZQ does not induce hprt mutations, but that cysticerci by themselves or together with palliative treatment administered to NC patients could induce mutations in some patients.
Montero
R
R
Instituto de Investigaciones Biomédicas, UNAM, Ciudad Universitaria, México D.F., Mexico.
Flisser
A
A
Madrazo
I
I
Cuevas
C
C
Ostrosky-Wegman
P
P
D000293:Adolescent; D000328:Adult; D000368:Aged; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D003551:Cysticercosis / Q000188:drug therapy* / Q000235:genetics*; D005260:Female; D005787:Gene Frequency; D006801:Humans; D007041:Hypoxanthine Phosphoribosyltransferase / Q000235:genetics*; D007700:Kinetics; D008214:Lymphocytes / Q000187:drug effects / Q000201:enzymology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D016296:Mutagenesis; D009153:Mutagens / Q000633:toxicity*; D009422:Nervous System Diseases / Q000188:drug therapy* / Q000235:genetics / Q000469:parasitology; D011223:Praziquantel / Q000627:therapeutic use / Q000633:toxicity*; D012016:Reference Values
D009153:Mutagens; D011223:Praziquantel; D007041:Hypoxanthine Phosphoribosyltransferase